Joint Stock – Sofrelop http://sofrelop.com/ Mon, 21 Nov 2022 14:49:28 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://sofrelop.com/wp-content/uploads/2021/06/icon-6-150x150.png Joint Stock – Sofrelop http://sofrelop.com/ 32 32 Warren Buffett loves this passive income stock https://sofrelop.com/warren-buffett-loves-this-passive-income-stock/ Mon, 21 Nov 2022 14:23:00 +0000 https://sofrelop.com/warren-buffett-loves-this-passive-income-stock/ McKesson (MCK 0.34%), a leading distributor of pharmaceutical and medical supplies, is a favorite with institutional investors. This includes Warren Buffett Berkshire Hathaway, who owns 3.2 million shares of the company, which are worth more than $1.1 billion. Berkshire Hathaway initiated its position in McKesson in the first quarter of this year by buying nearly […]]]>

McKesson (MCK 0.34%), a leading distributor of pharmaceutical and medical supplies, is a favorite with institutional investors. This includes Warren Buffett Berkshire Hathaway, who owns 3.2 million shares of the company, which are worth more than $1.1 billion. Berkshire Hathaway initiated its position in McKesson in the first quarter of this year by buying nearly 3 million shares, then adding 276,000 more and the second trimester. He did not buy any additional shares of McKesson in the third quarter, but maintained his position.

The stock is up more than 48% so far this year and there are plenty of reasons Buffett might like it, including strong top line and bottom line results. The company has increased annual revenue by 116% over the past 10 years and increased annual earnings per share (EPS) by 29% over the same period.

Reward shareholders

Stock is also a reliable source of passive income. The company has increased its dividend for 15 consecutive years and has increased the quarterly payout by 170% over the past decade.

McKesson has increased its quarterly dividend by 15% this year to $0.54 per share, giving it a yield of just under 0.6%. That’s below the S&P 500 average (1.82%), but with a cash dividend payout ratio of just 7.14%, it’s extremely safe and has plenty of room for growth. McKesson completed $1.5 billion in share buybacks in the last quarter, with another $5.8 billion authorized for the remainder of the fiscal year. This is good news for shareholders because redemptions reduce the number of shares, increasing earnings per share.

McKesson reported quarterly results Nov. 1, reporting revenue of $70.2 billion, up 5% year-over-year, and EPS of 6.46. $, up 278% from the same period a year ago. The company also raised its full-year guidance for Adjusted EPS from $24.45 to $24.95, up from the previous estimate of between $23.95 and $24.65.

MCK turnover (annual) given by Y-Charts

Streamline your business

McKesson attributed the revenue growth to an increase in its U.S. pharmaceuticals segment, which saw revenue jump 12% from the same period last year as the company said it had more product sales. specialty products and that its retail customers have increased the volume of their orders. Its prescription technology solutions segment reported revenue of $1 billion, up 9% year-on-year, driven by higher technology services revenue and increased prescription sales in the Company’s third-party logistics business.

Revenue fell 25% from its international segment, to $6.9 billion. This is due to the company’s decision to streamline its overseas operations. It has already divested in 11 of the 12 European countries in which it operates, selling to the Phoenix group. The only country with which it is still in the process of divesting its European activities is Norway.

The company said it expects revenue growth of 12-15% this fiscal year for its U.S. pharmaceutical segment and revenue growth of 10-16% for the prescription technology solutions segment. Its forecasts foresee a drop of 4% to 8% over the year for its medical solutions segment, and, thanks to its European disposals, a drop of 42% to 46% in the international segment.

The hunt for extra income

McKesson made some big moves in the last quarter that could help it boost its long-term revenue. On Nov. 1, he closed his deal to buy RxSavings Solutions, which works to bring transparency to prescription pricing, for up to $875 million.

RxSavings Solutions is a 10-year-old Kansas City-area startup that uses software to help consumer and employer health plans save money on prescription drug costs. It has 17 million members and made around $40 million in revenue in 2021. The idea is that McKesson’s resources will help RxSavings grow its membership, and the company should fit in well. in McKesson’s Prescribing Technology Solutions segment.

McKesson has also extended its partnership to distribute pharmaceutical products to SVC Health through 2027. CVS is McKesson’s largest customer, as the company supplies medications to CVS Health’s Caremark postal and specialty pharmacies. The two companies have worked together since 2001, and in fiscal 2022, the deal with CVS Health was responsible for 21% of McKesson’s revenue.

The Health care The company is also focusing more on its oncology offerings. It is expected to enter into a joint venture with the Sarah Cannon Research Institute of Health HCA to sponsor clinical research in oncology and accelerate drug development. As part of the partnership, McKesson purchased Genospace, which uses genomics to do precision medicine, particularly in oncology, and works to improve the process of matching patients for clinical trials.

Why Buffett May Like the Stock

Since Warren Buffett’s Berkshire Hathaway bought the stock in the first and second quarters, many investors have been interested in the company. Buffett likes to invest in stable businesses, and McKesson offered a reasonable price. Even with its shares on the rise, McKesson is trading for just 25 times earnings. It’s a solid company with a lot of growth potential. He rewarded investors with stock buybacks and steady dividend increases.

While there are always concerns about how a possible recession might hit the market, if you own McKesson shares, that’s less of a concern because its diversity of income sources protects it against a market downturn. And it deals with prescription drugs, which people have to take, whether the economy is good or bad.

Jim Halley has positions in CVS Health. The Motley Fool holds positions and recommends Berkshire Hathaway (B shares). The Motley Fool recommends CVS Health, CVS Health Corporation, HCA Healthcare, and McKesson and recommends the following options: long buy $200 in January 2023 on Berkshire Hathaway (B shares), short buy $200 in January 2023 on Berkshire Hathaway (stock B) and short January 2023 $265 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.

]]>
From the barter trade in ancient Mesopotamia to the “capitalism of nothingness” of the 21st century, part I, by Luis Martínez-Fernández https://sofrelop.com/from-the-barter-trade-in-ancient-mesopotamia-to-the-capitalism-of-nothingness-of-the-21st-century-part-i-by-luis-martinez-fernandez/ Sat, 19 Nov 2022 03:34:58 +0000 https://sofrelop.com/from-the-barter-trade-in-ancient-mesopotamia-to-the-capitalism-of-nothingness-of-the-21st-century-part-i-by-luis-martinez-fernandez/ A day between 2063 and 2060 BC. AD, in the extinct Sumerian city of Drehem, on the outskirts of the also extinct city of Nippur (in present-day Iraq), a public scribe recorded the shedding of 574 cowhides. In exchange of what ? The cuneiform tablet does not say so, but it could have been silver, […]]]>

A day between 2063 and 2060 BC. AD, in the extinct Sumerian city of Drehem, on the outskirts of the also extinct city of Nippur (in present-day Iraq), a public scribe recorded the shedding of 574 cowhides. In exchange of what ? The cuneiform tablet does not say so, but it could have been silver, textiles, pottery, or any number of tangible valuables. Another clay tablet, dated to the sixth year of Amar-Suen (2039 BC), reflects the payment of wages to 366 day labourers, possibly temple construction workers, receiving a indefinite quantity of goods. It could be barley, clothes, dates (the fruit) or beer. Such was the pre-coinage barter system of the ancient Mesopotamians.

Fast forward about 4,080 years and read this week’s economic headlines. World’s richest man, Elon Musk, protagonist of history’s greatest buyer’s remorse drama, told senior Twitter executives that ‘bankruptcy isn’t out of the question’; Sam Bankman-Fried, the eccentric founder of cryptocurrency firm FTX, sees a $32 billion valuation crash in 3-4 days. Wikipedia has already updated (downgraded) it from “billionaire” to “former billionaire”.

So how did we go from bartering goats for barley and beer for labor to what is increasingly becoming a nothingness economy, where PayPal generates $7 billion in revenue every quarter by charging fees for digital money transactions; and so-called influencers (an unfortunate term) monetize (another unfortunate term) uploaded dancing and daring videos to TikTok and other digital dumps of nothingness.

Well, it’s a long history punctuated with pivotal moments that include the emergence of money, money lending, for-profit trading, stock companies, the futures market, the internet, and more. recently, cryptocurrency.

COWS, COWRIES AND FIRST COINS

When cows (Bos taurus) and other forms of livestock were first domesticated around 10,500 years ago in the Middle East and later in the Indus Valley region (Bos indicus), they became a valuable and practical form of proto-currency. The Latin word for money, “pecunia”, is derived from “pecus”, Latin for cattle. The English words “cattle” and “chattel” (movable property) share a common etymology with “capitalism”: the medieval Latin word “capital” (property or stock). In present-day southern Sudan, members of the Mundari and Dinka tribes still use cattle as currency, dowry, and to pay fines in dispute resolution procedures conducted by tribal elders. Due to the prevalence of cattle rustling, herders are armed with long automatic weapons, as if protecting a bank vault.

Other forms of ancient currency include salt, which was used in Greece to buy slaves, hence the phrase “not worth its weight in salt”. In Rome, soldiers were often paid in salt. The Latin term “salarium argentum” means salty silver, and “argentum” translates to “silver”, which was used to mint dinars and other denominations of currency.

Unlike salt, which is essential in human nutrition, and livestock, which have intrinsic value as transport animals and sources of meat, milk, fat, leather, horn and much more, later forms of nonmonetary money had symbolic (arbitrary) value. This was the case with gold and silver, for example, because of their rarity. Around 1200 BC. In China, the rest of Asia and the Indian subcontinent, cowries (no relation to cows; they are a type of shell) became the preferred form of currency. The pre-Columbian Aztecs and Mayans gave cocoa beans a special value, contradicting many parents’ warning that money doesn’t grow on trees. When English explorer Thomas Cavendish landed on the Pacific coast of Mexico in 1587, he raided a Spanish customs office which included 400 bags of cocoa beans, each bag valued at approximately 10 silver crowns ( or 1/4 pound).

Numismatists agree that the oldest coins date from 610-600 BC. AD, minted in Lydia, present-day Turkey. Made of electrum, a natural alloy of gold and silver, these early coins were struck only on one side with images of roaring lions, emblematic of the Lydian kings. The use of coins quickly spread throughout the Greek world and in Persia.

Luis Martinez-Fernandez is the author of “Revolutionary Cuba: A History” and the forthcoming book “When the World Turned Upside Down: Politics, Culture, and the Unimaginable Event of 2019-2022.” Readers can attach it to [email protected] To learn more about Luis Martinez-Fernandez and read articles by other Creators Syndicate writers and cartoonists, visit the Creators Syndicate website at www. creators.com.

Photo credit: 652234 at Pixabay

]]>
Live Updates: U.S. retail sales beat forecast with biggest jump since January https://sofrelop.com/live-updates-u-s-retail-sales-beat-forecast-with-biggest-jump-since-january/ Wed, 16 Nov 2022 18:45:42 +0000 https://sofrelop.com/live-updates-u-s-retail-sales-beat-forecast-with-biggest-jump-since-january/ The interior of Mercedes’ EQS electric sedan © Getty Images for Mercedes-Benz Mercedes-Benz Group has slashed prices of some electric car models in China, joining a list of automakers that have followed suit Tesla’s price drop last month, in the latest sign of slowing demand in the world’s biggest market for electric vehicles. The starting […]]]>

The interior of Mercedes’ EQS electric sedan © Getty Images for Mercedes-Benz

Mercedes-Benz Group has slashed prices of some electric car models in China, joining a list of automakers that have followed suit Tesla’s price drop last month, in the latest sign of slowing demand in the world’s biggest market for electric vehicles.

The starting prices of the EQE model, EQS model and its luxury edition – the AMG EQS 53 model – sold in China will be reduced by Rmb50,000 ($7,000), Rmb204,600 and Rmb198,600, respectively, a said the German automaker. .

“We aim to flexibly adjust operating strategies in response to changing market demands,” the company said in a statement.

Mercedes-Benz faces intensifying competition from local rivals in the process of electric and digital transformation, Daimler China Director Hubertus Troska said at the China International Import Expo earlier this month, reported official media.

In October, Tesla cut prices for its Model 3 and Model Y sedans in China. Within days of Tesla’s move, Ford Motor’s EV arm and Aito, a Huawei-backed EV brand, followed suit.

Analysts have warned of a price war in the country’s increasingly crowded electric vehicle sector.

“This lower price strategy would generate overall negative sentiment,” Citigroup analyst Jeff Chung wrote in a research note, citing slowing growth in electric vehicle sales due to economic headwinds and zero checks. -Covid in China.

Chung added that Tesla’s move would also put pressure on other premium electric car makers, including XPeng, Volkswagen and BYD.

According to data from the China Association of Automobile Manufacturers.

]]>
Should investors buy the dip in Beyond Meat Stock? https://sofrelop.com/should-investors-buy-the-dip-in-beyond-meat-stock/ Sun, 13 Nov 2022 16:59:00 +0000 https://sofrelop.com/should-investors-buy-the-dip-in-beyond-meat-stock/ Beyond meatit is (NASDAQ: BYND) the stock fell 9% to a new all-time low on Nov. 9 in response to its third-quarter earnings report. The plant-based meat maker’s net revenue fell 22.5% year-over-year to $82.5 million and missed analysts’ expectations of 2.1 million of dollars. Its net loss fell from $54.8 million to $101.7 million, […]]]>

Beyond meatit is (NASDAQ: BYND) the stock fell 9% to a new all-time low on Nov. 9 in response to its third-quarter earnings report. The plant-based meat maker’s net revenue fell 22.5% year-over-year to $82.5 million and missed analysts’ expectations of 2.1 million of dollars. Its net loss fell from $54.8 million to $101.7 million, resulting in a loss of $1.60 per share and significantly missing the consensus forecast of $0.45.

Beyond Meat expects its revenue to decline 9% to 14% for the full year, which would represent a significant slowdown from its 14% growth in 2021, its 37% growth in 2020 and its growth by 239% in 2019. This continued deceleration, along with its mounting losses, chased the bulls away and attracted a sloth bear. But could Beyond Meat’s sharp decline also represent a long-term multibagger opportunity for investors?

Image source: Beyond Meat.

Beyond Meat faces an existential crisis

Beyond Meat sprouted like a weed in 2019 as restaurants and retailers eagerly jumped on the bandwagon for plant-based meat products. But in 2020, the pandemic closed restaurants and pushed budget-conscious consumers back to cheaper animal meat products. This slowdown persisted throughout 2021 and was exacerbated by stiff competition from Impossible Foods, Kelloggfrom Morningstar Farms, and Tyson Foods‘ vegetable meats division.

Beyond Meat initially thought its business would stabilize in 2022. In its May first-quarter report, it forecast revenue to grow 21% to 33% for the full year. But he cut that forecast to just 1% to 12% growth in August, followed by another guide cut last month, which was reiterated in its current full year downside outlook.

Beyond Meat blamed the drop primarily on inflation, which caused shoppers and restaurants to buy cheaper animal protein instead of its plant-based products, as well as increased competition. These headwinds are also compressing its margins by limiting its pricing power, forcing it to liquidate excess inventory, and increasing its production and transportation costs.

Its sales of Beyond Meat Jerky through a joint venture with PepsiCo, which generates much lower margins than its main chilled products, is putting further pressure on its gross margin. Beyond Meat also paid some of its co-manufacturing partners, including PepsiCo, underutilization and termination fees for not producing and selling enough product.

As a result, Beyond Meat’s gross margin turned negative in the first nine months of 2022, compared to its positive gross margins of 25% in 2021 and 30% in 2020. It expects its margin gross remains negative in the fourth quarter, but is also improving. slightly on a sequential basis as it pays less underutilization and termination fees. But despite this slight improvement, its margins are likely to remain negative and its losses are expected to widen for the foreseeable future.

The Bullish Case for Beyond Meat’s Long-Term Recovery

Beyond Meat’s declining revenue, negative gross margin, and rising losses, all strongly indicate that the plant-based meat craze may be over. However, the company still believes its operating cash flow will turn positive by the second half of 2023 as it aggressively cuts costs and scales its business. It has already laid off more than a fifth of its workforce in the past 12 months and estimates the reduction will reduce its total operating expenses by about $39 million over the next 12 months.

The company also plans to liquidate more of its inventory, reduce its ability to cut costs and address underutilization charges, and continue to focus on its long-term development of new plant-based products. beef, pork and poultry base.

During the conference call, CEO Ethan Brown said Beyond Meat will maintain its “unwavering focus” on the $1.4 trillion total addressable market for plant-based meat products. As for the competition, Brown expects a “disruption” to occur as more of his rivals “step back or consolidate a less crowded playing field”.

Brown also believes that plant-based meat products will achieve price parity with their animal-based counterparts over the long term, thanks to economies of scale, better brand recognition and less reliance on marketing campaigns. marketing and promotional partnerships.

In short, the next few quarters will be tough, but Beyond Meat still expects to be the last man standing in the plant-based meat industry. Unfortunately, its net loss nearly tripled year-over-year to $299 million in the first nine months of 2022, and it ended the third quarter with just $390 million in cash and cash equivalents as she was carrying $1.1 billion in debt.

In this context, a reduction of $39 million in its annual operating expenses does not seem aggressive enough. That’s why bears are still betting heavily on Beyond Meat’s continued decline with 37% of its shares outstanding. always short circuit to October 13. Beyond’s enterprise value of $1.54 billion (which includes its debt) also values ​​the company at more than three times next year’s sales — so it can’t yet be considered a bargain.

Therefore, Beyond Meat looks more likely to fall to zero rather than more than double to reach its initial public offering price again. Investors should consider avoiding this struggling trending stock and sticking to more reliable options like PepsiCo instead.

10 stocks we like better than Beyond Meat, Inc.
When our award-winning team of analysts have stock advice, it can pay to listen. After all, the newsletter they’ve been putting out for over a decade, Motley Fool Equity Advisortripled the market.*

They have just revealed what they believe to be the ten best stocks for investors to buy now…and Beyond Meat, Inc. was not one of them! That’s right – they think these 10 stocks are even better buys.

View all 10 stocks

* Portfolio Advisor Returns as of November 7, 2022

Leo Sun has no position in the stocks mentioned. The Motley Fool has positions and recommends Beyond Meat, Inc. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

]]>
Proxy form for holders of H Shares to be used at the Third Extraordinary General Meeting 2022 of the Company to be held on Thursday, December 15, 2022 https://sofrelop.com/proxy-form-for-holders-of-h-shares-to-be-used-at-the-third-extraordinary-general-meeting-2022-of-the-company-to-be-held-on-thursday-december-15-2022/ Fri, 11 Nov 2022 06:45:03 +0000 https://sofrelop.com/proxy-form-for-holders-of-h-shares-to-be-used-at-the-third-extraordinary-general-meeting-2022-of-the-company-to-be-held-on-thursday-december-15-2022/ US Regulated Stock Markets (Alternate Disclosure) via PUBT CHINA LIFE INSURANCE COMPANY LIMITED (A public limited company incorporated in the People’s Republic of China limited liability) (Stock code: 2628) PROXY FORM FOR HOLDERS OF H SHARES TO BE USED DURING THE THIRD EXTRAORDINARY GENERAL MEETING 2022 OF THE COMPANY TO BE HELD ON THURSDAY, DECEMBER […]]]>


US Regulated Stock Markets (Alternate Disclosure) via PUBT

CHINA LIFE INSURANCE COMPANY LIMITED

(A public limited company incorporated in the People’s Republic of China limited liability)

(Stock code: 2628)

PROXY FORM FOR HOLDERS OF H SHARES TO BE USED DURING THE THIRD EXTRAORDINARY GENERAL MEETING 2022

OF THE COMPANY TO BE HELD ON THURSDAY, DECEMBER 15, 2022

Number of shares to which this form of proxy relates 2

I … U.S 3 of 3

(address appearing in the register of members) being shareholder(s) of CHINA LIFE INSURANCE COMPANY LIMITED (there “Company“) appoints the President of the Assembly or 4

of

as my/our proxy to attend, act and vote for me/us and on my/our behalf at the 2022 Third Extraordinary General Meeting of the Company to be held at Multifunctional Hall, 2/F, Block A, Chinese life square, 16 financial street, Xicheng County, Beijing, ChinaThursday, December 15, 2022 at 9:30 a.m. and any adjournment thereof as set forth below with respect to the resolutions set forth in the notice of the third extraordinary general meeting 2022 dated November 10, 2022and, if no indication is given, as my/our attorney considers appropriate.

ORDINARY RESOLUTIONS

FOR 5

VERSUS 5

ABSTENTION 5

  1. Consider and approve the election of Mr. Zhao Feng as non-executive director of the seventh session of the Company’s Board of Directors.
  2. Consider and approve the election of Mr. Yu Shengquan like a Non-Executive Director of the seventh session of the Company’s Board of Directors.
  3. To consider and approve the election of Ms. Zhuo Meijuan as non-executive director of the seventh session of the Company’s Board of Directors.

Date

2022

Signature(s) 6:

Remarks:

  1. Important: You must first read the notice convening the third extraordinary general meeting 2022 (the “notice”) and the shareholders’ circular issued by the Company on November 10, 2022 before appointing a proxy.
  2. Please insert the number of shares registered in your name(s) to which this form of proxy relates. If no number is inserted, this form of proxy will be deemed to relate to all the shares of the Company registered in your name(s).
  3. Please insert the full name(s) (in Chinese or English) and address(es) (as listed in the membership register) in capital letters.
  4. If a proxy other than the Chairman of the Meeting is preferred, delete the words “the Chairman of the Meeting or” and insert the name and address of the desired proxy in the space provided for this purpose. A shareholder may appoint one or more proxies to attend and vote in his place. A proxy need not be a shareholder of the Company. The proxy of a shareholder who has appointed more than one proxy may only vote on one ballot.ANY AMENDMENTS TO THIS FORM OF PROXY MUST BE DULY
    PARAPELLED BY THE PERSON WHO SIGNS IT.
  5. IMPORTANT: IF YOU WISH TO VOTE FOR A RESOLUTION, PLEASE CHECK THE “FOR” BOX. IF YOU WISH TO VOTE AGAINST A RESOLUTION, PLEASE CHECK THE BOX INDICATED “AGAINST”. IF YOU WISH TO OPT-OUT, PLEASE CHECK THE “OPT-OUT” BOX.If you do not indicate how you want your proxy to vote, your proxy may exercise its discretion. Unless otherwise specified by you in this form of proxy, your proxy will also be entitled to vote at its discretion on any resolution properly submitted to the third extraordinary general meeting of 2022 other than those referred to in the notice. Abstained shares will be taken into account for the calculation of the required majority.
  6. This form of proxy must be signed by you or your agent duly authorized in writing or, in the case of a corporation, must be signed under seal or in the hand of a director or agent duly authorized to sign it . If this form of power of attorney is signed by an agent of the principal, the power of attorney authorizing this agent to sign, or any other document of authorization, must be notarized.
  7. When there are co-holders of shares, each of these persons may vote at the Third Extraordinary General Meeting 2022, either personally or by proxy, in respect of these shares as if they were solely entitled to do so. However, if several of these co-holders are present at the Third Extraordinary General Meeting 2022, either personally or by proxy, the person present whose name appears first in the register of shareholders for these shares will only have the right to vote. with regard to it.
  8. To be valid, for holders of H Shares, this form of proxy, together with the notarized proxy or other authorization documents, must be delivered to the registrar of the Company’s H Shares, Computershare Hong Kong Investor Services Limited on the 17M floor, Hopewell Centre, 183 Queen’s Road EastWanchai, hong kong at least 24 hours before the time set for the third extraordinary general meeting 2022 (i.e. no later than 9:30 a.m. on December 14, 2022) or any postponement thereof.

STATEMENT OF COLLECTION OF PERSONAL INFORMATION

  1. “Personal Data” in these statements has the same meaning as “personal data” in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of hong kong (“PDPO”).
  2. Your provision of Personal Data to the Company is voluntary. If you do not provide sufficient information, the Company may not be able to process your proxy and instructions.
  3. Your personal data may be disclosed or transferred by the Company to its subsidiaries, its share register and/or to other companies or bodies for any of the stated purposes, and retained for the period necessary for our purposes of verification and recording.
  4. You have the right to request access to and/or correction of your personal data in accordance with the provisions of the PDPO. Any request to access and/or correct your personal data must be made in writing to the personal data privacy officer of Computershare Hong Kong Investor Services Limited on the 17M floor, Hopewell Centre, 183 Queen’s Road EastWanchai, hong kong.

Disclaimer

China Life Insurance Co.Ltd. published this content on November 10, 2022 and is solely responsible for the information contained therein. Distributed by Audienceunedited and unmodified, on November 11, 2022 06:35:55 ​​UTC.

]]>
Soudah Development announces its participation in the Saudi Green Initiative Forum https://sofrelop.com/soudah-development-announces-its-participation-in-the-saudi-green-initiative-forum/ Tue, 08 Nov 2022 10:50:14 +0000 https://sofrelop.com/soudah-development-announces-its-participation-in-the-saudi-green-initiative-forum/ Saudi Arabia: Soudah Development (SD), a private equity real estate development company wholly owned by the Public Investment Fund, today announced its participation in the 2nd Saudi Green Initiative Forum, which will take place from 11 to November 12, accompanied by a gallery which from November 7 to 18 under the theme “From ambition to […]]]>

Saudi Arabia: Soudah Development (SD), a private equity real estate development company wholly owned by the Public Investment Fund, today announced its participation in the 2nd Saudi Green Initiative Forum, which will take place from 11 to November 12, accompanied by a gallery which from November 7 to 18 under the theme “From ambition to action”, bringing together government and business leaders, heads of international organizations, as well as experts in sustainability, environment and energy, to build on progress towards its climate action goals. The Saudi Green Initiative Forum is taking place on the sidelines of the United Nations Climate Change Conference (COP 27) in Sharm el-Sheikh, Egypt.

SD’s initiatives include a plan to plant more than one million trees by 2030, reintroduce endangered wildlife species – like the ibex – into their natural habitats, and conserve the extraordinary biodiversity to accelerate a greener future through three landmark sustainability initiatives demonstrating its commitment to protect, restore and re-wild the Kingdom’s highest peak.

This year, Soudah Development is continuing its reforestation efforts to increase vegetation cover and help restore natural mountain ecosystems by reintroducing 23 ibexes to their natural mountain habitat and re-rescuing the vital biodiversity natural areas of Soudah and Rijal Almaa, with the aim of contributing to the goals of the Saudi Green Initiative, which include reducing emissions by more than 278 million tonnes per year by 2030, planting 10 billion trees and increasing protected areas to more than 30% of the total marine and terrestrial areas.

“We are delighted to return to the Saudi Green Initiative Forum and look forward to demonstrating our commitment to sustainability, responsible tourism and the Kingdom’s overall environmental goals,” said Saleh Aloraini, CEO of Soudah Development. “Our initiatives aim to restore the natural ecosystem on the Kingdom’s highest peak allowing nature to take care of itself. With unique natural resources and dense vegetation cover, the project area has extraordinary biodiversity that We are committed to retaining leaders gather in Egypt, we look forward to using this historic conference to promote a new era of sustainable mountain tourism in Saudi Arabia and establish Sudah as one of the world’s leading sustainable destinations.”

Soudah Development’s sustainable development efforts have received strong recognition from the United Nations. During the 77th UN General Assembly, a global report by the UN Secretary General highlighted SD as the only Gulf developer to join the UN Mountain Partnership – a voluntary organization with over 400 global members , including governments, public entities, private companies and civil society groups committed to improving the lives of local communities and protecting mountain ecosystems.

-Ends-

]]>
Aurora Spine is now a game changer (OTCMKTS:ASAPF) https://sofrelop.com/aurora-spine-is-now-a-game-changer-otcmktsasapf/ Sat, 05 Nov 2022 06:34:01 +0000 https://sofrelop.com/aurora-spine-is-now-a-game-changer-otcmktsasapf/ chaofann/iStock via Getty Images Aurora Thorn (OTCQB: ASAP) (TSXV:ASG: CA), is a minimally invasive spinal implant technology company that I featured at Seeking Alpha in this article. The stock price is around 40% lower since this article was released in May 2021, but the stock price is bouncing back and has gained 30% since my […]]]>

chaofann/iStock via Getty Images

Aurora Thorn (OTCQB: ASAP) (TSXV:ASG: CA), is a minimally invasive spinal implant technology company that I featured at Seeking Alpha in this article. The stock price is around 40% lower since this article was released in May 2021, but the stock price is bouncing back and has gained 30% since my previous update published in June. The initial price decline was accompanied by unfavorable market conditions relative to microcap growth stocks and the recent uptrend reflects Aurora’s progress in its transformation from a third-party reseller to a market-changing organics company. given.

Investment thesis

The record revenues recorded in Q1 It was the first time the company had shown higher organic product sales than third-party sales. Since then, the company has won FDA 510(k) approval for two products, a second DEXA platform product and an advanced sacroiliac joint (“SI joint”) device. The DEXA platform and joint SI device are game changers, with a strong backbone provided by the company’s other two core products, SIP and SILO.

DEXA platform

Dawn patented DEXA technology is used to determine a patient’s bone density, which is then matched to the material of implant design to improve fixation and promote healthy bone growth, as described in this study. It’s important to note that doctors are very familiar with DEXA, but Aurora has acquired the patent and is the only company to offer bone-matching implantable devices.

The company has received FDA 510(k) permission for DEXA-C, a cervical cage, in August 2022. DEXA-C was introduced on a limited basis with only two doctors involved. The product introduction is now in beta with ten participating physicians and will enter full commercial phase this month.

The Company’s Second DEXA Technology Product, DEXA-L, a Lumbar Interbody Spinal Fusion System, Received FDA 510(k) permission in June. Each Aurora device requires a kit necessary for the preparation and installation of the device. Aurora said it now has 40 DEXA-C kits ready to ship, with the first DEXA-C procedure scheduled for December.

I expect DEXA-L to receive a similar market reaction to DEXA-C when introduced, gaining quickly 8% of Aurora’s total sales. The company plans to add additional products using DEXA technology, as well as license the technology to third parties for uses outside of its core spine surgery competency, such as for dental and replacement appliances. of the knee. I believe the DEXA platform will be Aurora’s flagship product and cross-sell its other products.

SILO TFX

Aurora’s Allograft-Free Titanium Device Named SILO TFX Obtained FDA 510(k) permission last month. SI-Os (SIBN) is currently the market leader in minimally invasive sacroiliac joint (“SI joint”) devices. The SI-Bone device requires three incisions and three devices. The SILO TFX is a game changer as it only requires one incision and one device. Fewer incisions reduce the cost, complications and time of surgery.

SI joint fusion is in the early stages of being established as a preferred solution treatment alternative to invasive surgery for back pain caused by a ruptured SI joint. SILO TFX patients are seen on an outpatient basis for a procedure that lasts approximately one hour. The patient is able to walk immediately after the procedure.

TFX will have a slower rollout than DEXA products because doctors are familiar with DEXA technology and don’t need training. Aurora hosts monthly physician training programs for its ZIP and Silo products and will now add TFX training. A DEXA version of the TFX device is expected to be introduced next year.

TFX sales will benefit from a new code for insurance reimbursement that requires transfixation of the SI joint. This will eliminate many competitive SI seal devices that do not meet this requirement. An explanation of how Aurora’s devices meet the requirement is included in this recent interview (approximately 8 minutes) with Aurora CEO Trent Northcutt.

ZIP*: ENGLISH

Aurora’s first biologic product, ZIP, received 510(k) clearance from the FDA in 2013 and became commercially available in 2014. The ZIP is a minimally invasive device, requiring no medical screws and a single incision. For a more detailed description of Zip devices, please see my previous articles or the Company Website.

ZIP was Aurora’s flagship product, accounting for nearly 31% of total sales in the second quarter. Aurora recently increased the total addressable market for ZIP by obtaining additional FDA clearance for the ZIP device, allowing physicians to treat patients with lumbar spinal stenosis with the ZIP implant device. ZIP sales are also supported by strong early results from a clinical study which demonstrated that the ZIP was effective in relieving pain in 64% of patients who received the device, exceeding the 50% success threshold.

SILO

It’s likely that TFX will cannibalize sales and eventually replace Aurora’s SILO-C, a allograft device that fuses the pelvis to the joint, requiring no screws. The TFX provides better fixation because it uses two screws and the titanium lasts longer than the allograft material. SILO-C accounted for nearly 24% of total sales in the second quarter.

BUZZ

In the interview quoted above Aurora CEO Trent Northcutt has revealed there is interest in his company’s products from industry giants who tend to acquire small companies with disruptive products, as well as the interest of some analysts. There is also a lot of buzz on social networks. Do a LinkedIn search on Aurora Spine and you’ll find recommendations from physicians who have attended an Aurora training session, gone home, become clients, and have endorsed Aurora Spine on LinkedIn.

The buzz is being generated because Aurora offers superior products in a fledgling industry. Aurore received the Best Spine Technology Award for its DEXA technology at the North American Spine Society’s annual event last week. Benefits of non-invasive benefits include less procedure time, less pain, fewer side effects for the patient and faster recovery time for the patient translate into the growth Surgical Centers in the United States Today there are roughly the same number of surgical centers as there are hospitals. Aurora Spine has already captured the largest pain surgery center in the United States, National Spine & Pain, as a client.

I included this section because where there is smoke, there is usually fire. Aurora is attracting attention from circles important to the success of its product as well as the success of the stock price.

finance

There are approximately 67 million shares outstanding. The market cap is around $27 million. The company recently reported approximately $1 million in cash and $3 million in debt, giving an EV of $29 million. There are approximately $4 million in accounts receivable reported at the end of the second quarter.

The company reported about $4 million in revenue for the second quarter and nearly broke even. Spending will now be reduced as the company currently has no products in the regulatory approval process and kits for its new DEXA product have already been paid for. Expanding the marketing of the two DEXA products and the TFX product should easily propel the business into profitability and, in my opinion, should at least double revenue over the next 12 months, which translates into a price ratio /futures sales of just over 1X ($32m revenue / $29m market cap).

Risks

The company has experienced delays due to supply chain issues, like many other companies. The supply chain bottleneck seems to be less prevalent, but the company could have a titanium supply problem in the future, as almost half of the world’s titanium comes from Russia and Ukraine. war-torn. The company bought titanium ahead of its needs to avoid a future supply problem, but there is no way of knowing how long the dispute between the two nations will last.

Collection turnaround time is a major concern for a company with as little cash as Aurora. The reported AR is significant and worth monitoring to see if the AR is reduced in the future. At this point, this is not a significant consideration because Aurora has not reported any outstanding accounts and because hospitals have been known to stretch payments due to low profit margins in the hospital industry.

Conclusion

Aurora posted record revenues before both DEXA products and the new TFX product were fully rolled out to the market. The investment thesis of this article is that these three new products are game changers. The company is on the verge of achieving profitability. The stock is selling at a modest valuation and is expected to revalue as new product sales increase.

]]>
HC questions the legitimacy of Nagad’s license https://sofrelop.com/hc-questions-the-legitimacy-of-nagads-license/ Wed, 02 Nov 2022 10:57:52 +0000 https://sofrelop.com/hc-questions-the-legitimacy-of-nagads-license/ Published: 02 November 2022 16:57:52 The High Court questioned the legitimacy of the license of Nagad, a mobile money company under the Bangladesh Post. Following a writ hearing on Wednesday, Judge Md Mozibur Rahman Miah and Judge Kazi Md Ejarul Haque Akondo of the High Court issued a rule asking why Nagad’s license would not […]]]>